Business
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Ho...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, Alberta\n \n ,\n \n April 8, 2021\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr.\n \n Matt Coffey\n \n , the Company's President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. Details on the panel discussion are provided below.\n \n \n \n Title:\n \n Off-the-Shelf CAR T - solid tumors, myeloma, lymphoma\n \n \n \n Date:\n \n \n Thursday, April 15, 2021\n \n \n \n \n Time:\n \n \n 8:15 am ET\n \n \n \n Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Canaccord representative or email\n \n [email protected]\n \n .\n \n \n \n About Oncolytics Biotech Inc.\n \n \n \n Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning \"cold\" tumors \"hot\" -- through innate and adaptive immune responses to treat a variety of cancers.\n \n \n Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit:\n \n www.oncolyticsbiotech.com\n \n .\n \n \n \n This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securi...